Georgios Schoretsanitis1, Andreas A Westin2, Julia C Stingl3, Kristina M Deligiannidis4, Michael Paulzen5, Olav Spigset6. 1. The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA. Electronic address: george.schor@gmail.com. 2. Department of Clinical Pharmacology, St Olav University Hospital, Trondheim, Norway. 3. Institute of Clinical Pharmacology, University Hospital of RWTH Aachen, Aachen, Germany. 4. Zucker School of Medicine, New York and The Feinstein Institutes for Medical Research, Manhasset, New York, USA. 5. Alexianer Hospital Aachen, Aachen, Germany, Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, and JARA - Translational Brain Medicine, Aachen, Germany. 6. Department of Clinical Pharmacology, St Olav University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Abstract
OBJECTIVE: Data regarding the ability of antidepressants to enter fetal, newborn and infant fluids have become gradually available, but mechanisms of antidepressant transfer remain poorly understood. Here we calculated penetration ratios in an array of matrices from combined samples of pregnant/breastfeeding women taking antidepressants. METHOD: We performed a systematic literature search of PubMed and EMBASE to identify studies with concentrations of antidepressants from maternal blood, amniotic fluid, umbilical cord blood and/or breast milk. Penetration ratios were calculated by dividing the concentrations in amniotic fluid, umbilical cord plasma or breast milk by the maternal plasma concentration. When data from multiple studies were available, we calculated combined penetration ratios, weighting the study mean by study size. RESULTS: Eighty-five eligible studies were identified. For amniotic fluid, the highest penetration ratios were estimated for venlafaxine (mean 2.77, range 0.43-4.70 for the active moiety) and citalopram (mean 2.03, range 0.35-6.97), while the lowest ratios were for fluvoxamine (mean 0.10) and fluoxetine (mean 0.11, range 0.02-0.20 for the active moiety). For umbilical cord plasma, nortriptyline had the highest ratio (mean 2.97, range 0.25-26.43) followed by bupropion (mean 1.14, range 0.3-5.08). For breast milk, the highest ratios were observed for venlafaxine (mean 2.59, range 0.85-4.85), mianserin (mean 2.22, range 0.80-3.64) and escitalopram (mean 2.19, range 1.68-3.00). CONCLUSION: We observed considerable variability across antidepressants regarding their ability to enter fetal, newborn and infant fluids. Measuring antidepressant concentrations in a maternal blood sample can provide a reliable estimate of fetal/infant exposure, although further evidence for concentration-dependent effects is required.
OBJECTIVE: Data regarding the ability of antidepressants to enter fetal, newborn and infant fluids have become gradually available, but mechanisms of antidepressant transfer remain poorly understood. Here we calculated penetration ratios in an array of matrices from combined samples of pregnant/breastfeeding women taking antidepressants. METHOD: We performed a systematic literature search of PubMed and EMBASE to identify studies with concentrations of antidepressants from maternal blood, amniotic fluid, umbilical cord blood and/or breast milk. Penetration ratios were calculated by dividing the concentrations in amniotic fluid, umbilical cord plasma or breast milk by the maternal plasma concentration. When data from multiple studies were available, we calculated combined penetration ratios, weighting the study mean by study size. RESULTS: Eighty-five eligible studies were identified. For amniotic fluid, the highest penetration ratios were estimated for venlafaxine (mean 2.77, range 0.43-4.70 for the active moiety) and citalopram (mean 2.03, range 0.35-6.97), while the lowest ratios were for fluvoxamine (mean 0.10) and fluoxetine (mean 0.11, range 0.02-0.20 for the active moiety). For umbilical cord plasma, nortriptyline had the highest ratio (mean 2.97, range 0.25-26.43) followed by bupropion (mean 1.14, range 0.3-5.08). For breast milk, the highest ratios were observed for venlafaxine (mean 2.59, range 0.85-4.85), mianserin (mean 2.22, range 0.80-3.64) and escitalopram (mean 2.19, range 1.68-3.00). CONCLUSION: We observed considerable variability across antidepressants regarding their ability to enter fetal, newborn and infant fluids. Measuring antidepressant concentrations in a maternal blood sample can provide a reliable estimate of fetal/infant exposure, although further evidence for concentration-dependent effects is required.
Authors: Victoria Hendrick; Zachary N Stowe; Lori L Altshuler; Sun Hwang; Emily Lee; Desiree Haynes Journal: Am J Psychiatry Date: 2003-05 Impact factor: 18.112
Authors: Ada M Loughhead; Zachary N Stowe; D Jeffrey Newport; James C Ritchie; C Lindsay DeVane; Michael J Owens Journal: Biol Psychiatry Date: 2005-11-02 Impact factor: 13.382
Authors: Jonathan Rampono; Stephanie Teoh; L Peter Hackett; Rolland Kohan; Kenneth F Ilett Journal: Arch Womens Ment Health Date: 2010-10-07 Impact factor: 3.633
Authors: P Baumann; C Hiemke; S Ulrich; G Eckermann; I Gaertner; M Gerlach; H-J Kuss; G Laux; B Müller-Oerlinghausen; M L Rao; P Riederer; G Zernig Journal: Pharmacopsychiatry Date: 2004-11 Impact factor: 5.788
Authors: Zachary N Stowe; Amy L Hostetter; Michael J Owens; James C Ritchie; Kevan Sternberg; Lee S Cohen; Charles B Nemeroff Journal: J Clin Psychiatry Date: 2003-01 Impact factor: 4.384
Authors: Evelyn D Lobo; Corina Loghin; Mary Pat Knadler; Tonya Quinlan; Lu Zhang; Jill Chappell; Richard Lucas; Richard F Bergstrom Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447